Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Clinuvel Pharmaceuticals ( (AU:CUV) ) is now available.
Clinuvel Pharmaceuticals has issued 227,158 fully paid ordinary shares at no issue price per share on 2 April 2026, confirming the shares were issued without a prospectus under Australian Corporations Act provisions. The company stated it remains compliant with its financial reporting and continuous disclosure obligations, and that there is no undisclosed information that would affect the value of these securities, supporting transparency for existing and prospective investors.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$27.90 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercialising treatments for genetic, metabolic, systemic and life-threatening acute disorders, as well as healthcare solutions for specialised populations. The company is a pioneer in photomedicine and melanocortin peptides, with its lead therapy SCENESSE approved in major markets as the first systemic photoprotective drug for adults with erythropoietic protoporphyria.
YTD Price Performance: -27.05%
Average Trading Volume: 113,937
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$456.3M
For an in-depth examination of CUV stock, go to TipRanks’ Overview page.